Setria® Glutathione is the No. 1 selling brand of glutathione in natural product supermarkets, according to SPINS, an industry source of health and wellness retail data and intelligence. The rating was for the 52 weeks ending Sept. 9, 2018.

Setria® is a clinically studied and patented glutathione manufactured by Kyowa Hakko Bio Co., Ltd. Its uses span immune support, skin health, detoxification support, and free radical support. More than 50 brands incorporate Setria® into dietary supplements.*

Glutathione — found in virtually every cell of the human body and known as the master antioxidant — is well-known for protecting cells from oxidative stress and toxins. Clinical studies show Setria® is absorbed by the body and that daily supplementation increases reduced glutathione levels in the blood making glutathione available for its supportive properties.1

Setria® plays a key role in protecting all kinds of cells from the damaging effects of ingested chemicals and potential carcinogens the body has already absorbed. It also assists in protein synthesis, DNA repair, enzyme function, transport, and cell maturation. Higher levels of glutathione also are associated with optimal physical and mental health. *

“The list of benefits glutathione provides our bodies is almost endless,” said Danielle Citrolo, PharmD, scientific and regulatory affairs manager, Kyowa Hakko USA. “We’re honored that consumers view Setria® as the go-to brand for supporting their health.”

Setria® is made via a patented, proprietary fermentation process that results in a form of glutathione that:
Boosts the body’s natural defense system*
Helps your body fight oxidative stress*
Promotes healthy aging and overall health*
Replenishes your body’s primary defense system*
Supports immune health*
Supports liver health by eliminating harmful toxins*

The loss of glutathione stores due to aging lowers the body’s defenses to harmful effects of sunlight and toxins. Setria® has been shown to help reduce wrinkles and support skin brightening. In addition, some consumers use glutathione as a skin brightener to lower melanin levels, which also helps fade aging spots.2 *

1 Richie JP Jr, Nichenametla S, Neidig W, Calcagnotto A, Haley JS, Schell TD, Muscat JE. Randomized controlled trial of oral glutathione supplementation on body stores of glutathione. European Journal of Nutrition. May 2014: 1436-6207. doi: 10.1007/s00394-014-0706-z
2 Weschawalit S, Thongthip S, Phutrakool P, Asawanonda P. Glutathione and its antiaging and antimelanogenic effects. Dove Press. 27 April 2017 Volume 2017:10 Pages 147—153. Doi: https://doi.org/10.2147/CCID.S128339
3 McKinley S, Andrew T, Morita M, Willoughby D. Combined L-Citrulline and Glutathione Supplementation Increases the Concentration of Markers Indicative of Nitric Oxide Synthesis. Journal of the International Society of Sports Nutrition. 2015, 12:27 https://jissn.biomedcentral.com/articles/10.1186/s12970-015-0086-7

*These statements have not been evaluated by the Food and Drug Administration. This product is not intended to diagnose, treat, cure, or prevent any disease.

October 30th, 2018 (Carthage, MO USA) Stratum Nutrition® announces they are recipients of the Frost & Sullivan 2018 North American Competitive Strategy Innovation and Leadership Award for the Joint Health Ingredient Industry for their NEM® brand eggshell membrane ingredient.

Frost & Sullivan recognizes Stratum Nutrition® with this award for NEM® based on several criteria. Frost & Sullivan analysts independently evaluated two key factors: Strategy Innovation and Customer Impact. Strategy Innovation takes into account the Strategy Effectiveness and Execution, as well as Competitive Differentiation, Executive Team Alignment, and Stakeholder Integration. The area of Customer Impact looks at Price/Performance Value, the Customer’s Purchase, Ownership & Service Experience, and Brand Equity.

Frost & Sullivan comments on the award:

“Stratum Nutrition’s NEM® offers highly effective and fast-acting joint health benefits supported by strong and growing scientific evidence. Its strategy and approach to vigorously pursue science to back its ingredients’ health benefits are best-in-class and unrivalled by any other competitors. Stratum Nutrition’s exceptional competitive strategy and multifaceted innovation approach to product development offers its customers unique opportunities to enhance the value of their own health products. This is altogether unmatched by other competitors and has earned Stratum Nutrition the market leading position.”

Competitive Strategy Innovation and Leadership is significant to achieve top-line growth and must take into account competitors, must meet customer demand with a comprehensive value-driven product, and must establish a brand that resonates deeply with customers standing apart from other providers. Success must be shown in brand, demand and positioning.

Multiple clinical trials have been conducted on NEM®, and more recently, a first of its kind, healthy population, joint health clinical study supports the use of pain and stiffness reduction label claims, as well as a cartilage protection label claim – with only 500 mg once a day.

“It’s an honor to receive this Frost & Sullivan award,” said Director of Brand & Product Strategy at Stratum Nutrition, Andrew Rice. “Our team’s passion to help others live healthier lives is the motivation for our unrelenting hunger to provide unique ingredients backed by unparalleled science, quality, and innovation.”

23 October 2018 (Kensington, PE Canada) — Last year the journal Nutrients published a novel mechanism by which consuming Ahiflower oil supports the body’s natural anti-inflammatory response, for example after strenuous exercise or immune challenge. Now the same team of Canadian researchers at the University of Moncton has just published a study that deepens our understanding of how Ahiflower oil’s natural anti-inflammatory support may be occurring. The research is reported in the journal Prostaglandins, Leukotrienes and Essential Fatty Acids 138 (2018), 33-44.

The Canadian research team has discovered that eicosatetraenoic acid (c20:4, n-3, ETA), a long-chain omega-3 molecule that is significantly elevated through Ahiflower Oil consumption, can be converted into two novel compounds associated with inflammation management.

Two previously published human clinical studies have shown that Ahiflower oil consumption rapidly improves tissue levels of ETA within 2-4 weeks. This occurs because Ahiflower oil is the richest source of omega-3 stearidonic acid (c18:4, n-3, SDA), the immediate metabolic precursor to ETA — meaning that our bodies convert SDA in Ahiflower oil very efficiently to ETA in circulating cells. Prior to the current study, no biologically active metabolites of ETA have ever been reported.

The University of Moncton team, led by Marc Surette and Kristine Gagnon, confirmed the novel identity and bio-activity of these molecules, as well as a specific anti-inflammatory mechanism of action for one of them. Importantly, the research suggests that consuming a plant-derived omega-3 oil rich in SDA may allow our bodies to produce functionally similar precursor compounds that accumulate when we consume marine omega-3 oils rich in eicosapentaenoic acid (c20:5, n-3, EPA) and docosahexaenoic acid (c22:6, n-3, DHA). This is because the newly discovered compounds are produced and mediated through similar enzymes (called lipoxygenases) in our cells as those deriving from marine and algal oils rich in EPA and DHA.

Commenting on this latest finding, Greg Cumberford of Natures Crops Incorporated said, “We are grateful to Dr. Surette and his Canadian research colleagues for delving deeply into the beneficial parallel role that plant-derived omegas like Ahiflower oil play in supporting natural anti-inflammatory response mechanisms, alongside marine omega sources. I personally believe that Ahiflower oil’s uniquely high SDA and anti-inflammatory GLA combination will continue to ‘cut new ice’ in our understanding of anti-inflammatory response support mechanisms. The researchers from Moncton are leading the way globally.”

A steady stream of recent scientific evidence in human and animal nutrition alike points to the validated role that Ahiflower oil plays as a sustainable, traceable, and meaningful alternative not only to other plant-based omega-3 oils like flax (linseed), chia, and hemp, but also traditional marine-based omega-3 sources.

Gnosis offers its customers a complete and personalized support, ranging from scientific to marketing, with the purpose of helping their business.

Today this flexibility translates into the offer of a new service: Gnosis is now able to provide most of the company’s videos in the following languages: English, Italian, French, Spanish, German and Chinese.

This multilingual service is thought and designed for all Gnosis customers around the world!
Visit our YouTube page and check with your eyes!
If your favorite video is not available in your language, do not hesitate to request it by writing to marketing@gnosis-bio.com.

This is the clear sign that Gnosis always anticipates your needs and never stops satisfying your expectations!

Folate deficiency and polymorphism of the enzymes involved in the folate cycle increase the risk of hyperhomocysteine, a recognized factor of many diseases as cognitive decline and neurological disorders (depression, dementia, Alzheimer), osteoporosis, diabetes, atherosclerosis and vascular diseases. Homocysteine is a metabolite of the one carbon metabolism, also named methylation cycle.

Gnosis aims at protecting human health with three blockbuster products:

Quatrefolic®, the glucosamine salt of (6S)-5-methyltetrahydrofolate, is the biologically active form of folate that completely bypasses the “damaged” MTHFR conversion step, overstepping the problem of people with polymorphisms in folate-related enzymes.

Adonat® (S-Adenosyl-methionine), the methyl donor for life, plays an important role in the metabolism of homocysteine: dysregulation in methylation status due to the reduced synthesis of SAMe is among the central mechanisms that explain the negative effect of hyperhomocysteinemia related to vascular diseases and neurodegenerative disorders, where synthesis in neurotransmitters and proteins – important for the structural integrity of the brain – is disrupted.

As high levels of homocysteine exert disease effects by the increase of oxidative stress damage, Emothion®, the effective – IN BODY – form of Glutathione, helps to restore our body as a greater antioxidant defense protecting the brain and acts as a free radical scavenger and inhibitor of lipid peroxidation.

If you want to discover more about homocysteine causes and solutions, ask for your copy of the new infographic.

A recently published case series study has evaluated the effect of 5-MTHF glucosamine salt (Quatrefolic®) in couples with recurrent miscarriages, lasting for at least 4 years.
5-MTHF glucosamine salt (Quatrefolic®) has been supplemented in a B vitamin complex and chelated zinc (Impryl®, Parthenogen, Switzerland or Tretrafolic®, Nurilia, France) at the dosage of 800 µg/day, according to the 5-MTHF glucosamine salt requirements in healthy women.

The study conclusion highlights that the conventional use of large doses of folic acid (5 mg/day) has become obsolete. A physiological dose of 5-MTHF glucosamine salt (800 μg) bypasses the MTHFR block and is suggested to be an effective treatment for couple fertility problems.

In the trial, the selected population shows a strong link between an impaired folate cycle, due to the presence of polymorphism of the enzyme methylentetrahydrofolate reductase (MTHFR), and consequently the capacity to achieve conception and carry a pregnancy to term.
The women distribution of the C677T was: Wild Type 38%, Heterozygous 45% and Homozygous 17%, very close to what is generally observed in Europe. Most of the women had been previously treated unsuccessfully with high doses of folic acid (5 mg/day).

There is now strong evidence indicating that MTHFR isoforms are detrimental for fertility in women and men; in all couples of the study, at least one of the partners was a carrier of one of the two main MTHFR isoforms.

Of 33 couples, 13 spontaneous pregnancies were observed at the end of the treatment and other 13 pregnancies were obtained after assisted reproductive technology (ART), with the overall ongoing pregnancy rate of 86.7%.

The supplementation with 5-MTHF (Quatrefolic®) instead of folic acid appears to be an effective treatment for patients carrying the above mutations, where the physiological dose of 5-MTHF glucosamine salt (800 μg) bypasses the MTHFR block.

On the contrary, excess of folic acid intake leads to the UMFA (Un-Metabolized Folic Acid) syndrome in this peculiar population; UMFA syndrome may increase the cancer risks and cause immune dysfunction.
UMFA generated by high doses of folic acid may induce a pseudo MTHFR syndrome via a mechanism of substrate inhibition, inducing a reversal of the cycle and a resulting increase in homocysteine (Hcy).

The study highlights the benefits of Quatrefolic®- the active folate form immediately bioavailable without metabolization of MTHFR enzyme – and the importance of scientific communication lead by Gnosis in these years.
Finished formulations with Quatrefolic® are in the limelight of new clinical studies, providing even more evidence of the real advantages respect to the folic acid, in term of efficacy and safety.

Kaneka Pharma Europe introduced a range of various application examples, answering the demands of today’s sportspeople for better performance and a healthy body

Brussels (Belgium), May 2018 – In line with the slogan #Powered by Ubiquinol, Kaneka highlighted at this year’s Vitafoods several options for combination products that target the emerging sports nutrition market. The key ingredient Ubiquinol™ is an essential part of the body’s respiratory chain and is scientifically proven to support endurance, overall performance and recovery. Working with its partners, Kaneka has developed nutraceutical supplements in various dosage forms, such as energy gels, powder sticks and a variety of capsules, all including specially stabilised Ubiquinol™.
A broad range of other ingredients are ideal for the production of powerful combinations – such as magnesium for rapid energy, vitamins and amino acids to promote recovery, and Kaneka’s unique ingredient Glavonoid™ to support muscle building.

The company’s patented and natural yeast-based production process makes it possible to deliver Ubiquinol™ in several stable application forms without any detrimental impact on efficacy. Granulate sticks, hard gelatine and chewable capsules as well as gels and liquids make supplementation easy, even on the move. Combinations with multivitamins, magnesium, carnitine and amino acids can be tailored to the needs of sportspeople who want to support their immune defence, rapid energy production or muscular capabilities.

Filip Van hulle, Senior Manager at Kaneka’s Quality of Life Division, is delighted with the excellent response the company’s sports prototypes received at Vitafoods: “The sports nutrition market is growing enormously, fuelled by interest from a deeper than ever pool of potential consumers who are well informed and focussed on innovative, backed-by-science ingredients. Our sports prototypes represent the tip of the iceberg of possibilities for developments in the future.”

Gnosis is excited to announce that the new clinical study on Mythocondro® – assessed to investigate the efficacy of the Non-Animal Chondroitin Sulfate in the treatment of moderate knee osteoarthritis – has been concluded with significant positive results achieved for all endpoints tested, and will be shortly published.
The randomized, double-blind, placebo controlled study was carried out in participation with the University of Pavia (Italy), on 60 individuals (male and female), supplemented with low dosage of Mythocondro® (600 mg/day) for 12 weeks, with endpoints set at T0, T1 (4 weeks) and at T2 (12 weeks).

Primary endpoints included the evaluation of:
•Pain intensity measured both in motion and at rest, using the Visual Analogue Scale (VAS).
•Assessment of knee function by WOMAC (Western Ontario and McMaster Universities Arthritis) Index.
•Assessment of Tegner Lysholm Knee Scoring (that measures how much knee pain has affected the ability to manage in everyday life).

Secondary endpoints evaluated:
•Health-related quality of life, recorded by the ShortForm36 (SF-36).
•Inflammation markers in plasma: C-reactive protein (CRP), erythrocyte sedimentation rate (VES)

All endpoint results show a statistically significant modification of the parameters with impressive results related to the decrease in the Womac Score and the Lysholm Knee Scoring Scale.
Gnosis, aware of the superior nature of Mythocondro® in terms of efficacy and safety, is investigating its short-term effects with the SCOPE study (non-animal CS in Obesity and Physical Exercise) to demonstrate the anti-oxidant, anti-inflammatory and chondroprotective properties at low dose.
More detailed information about the clinical program will be confidentially disclosed by Gnosis team to our exclusive partners at Vitafoods Europe exhibition, that will be held from May 15th to 17th in Geneva (booth #I40). Do not miss the chance to be one of them!
For more information contact marketing@gnosis-bio.com and visit www.mythocondro.com

At the next edition of Vitafoods ( Booth #I140), Gnosis will present the new Company Profile, the complete corporate brochure that lists the Group’s main features since its foundation, with a brief description of all Gnosis sites in Europe and abroad, and illustrating the two categories of products provided for the pharmaceutical and nutraceutical industries.

The Company Profile does not forget to describe Gnosis’ inspiration and customer-oriented mission, as well as the important commitment to quality and safety of the company, aimed at preserving both the human health and the environment.

All these contents have been incorporated into a new and modern graphics and are accompanied by exclusive photos of Operations, which can further appreciate the industrial expertise that characterize our company.